臨床泌尿器科60巻12号

2006年11月発行

特集 ここが知りたい―癌薬物療法

未治療前立腺癌に対する薬物療法

著者： 佐藤文憲¹ 三股浩光¹

所属機関： ¹大分大学医学部腫瘍病態制御講座（泌尿器科学）

ページ範囲：P.891 - P.895

文献概要

　未治療前立腺癌に対する根治療法は手術あるいは放射線療法であり，薬物療法は集学的治療の一環として，あるいは根治が望めない症例に適応される。術前内分泌療法は生存率の向上に寄与しないが，術後補助内分泌療法はリンパ節陽性例には有効である。内分泌療法併用放射線外照射を行う場合，リスクに応じた内分泌療法を計画すべきである。Maximum androgen blockade（MAB）療法はLH-RH agonist単独療法と比較して生存率をわずかながら改善する。間歇的内分泌療法の制癌効果についての結論は出ていない。今後ドセタキセルをはじめとした新規前立腺癌治療薬と根治療法の併用が治療成績を向上させる可能性がある。

参考文献

1）Debes JD and Tindall DJ：Mechanisms of androgen-refractory prostatecancer. N Engl J Med 351：1488-1490, 2004

2）Klotz LH, Goldenberg SL, Jewett MA, et al：Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol 170：791-794, 2003

3）Miyake H, Sakai I, Inoue TA, et al：The limited significance of a longer duration of neoadjuvant hormonal therapy prior to radical prostatectomy for high-risk prostate cancer in Japanese men. Urol Int 77：122-126, 2006

4）Bonney WW, Schned AR and Timberlake DS：Neoadjuvant androgen ablation for localized prostatic cancer：pathology methods, surgical end points and meta-analysis of randomized trials. J Urol 160：1754-1760, 1998

5）Scolieri MJ, Altman A and Resnick MI：Neoadjuvant hormonal ablative therapy before radical prostatectomy：a review. Is it indicated? J Urol 164：1465-1472, 2000

6）So A, Gleave M, Hurtado-Col A, et al：Mechanisms of the development of androgen independence in prostate cancer. World J Urol 23：1-9, 2005

7）Tannock IF, de Wit R, Berry WR, et al：Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351：1502-1512, 2004

8）Petrylak DP, Tangen CM, Hussain MH, et al：Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351：1513-1520, 2004

9）Southwest Oncology Group；Berry DL, Moinpour CM, Jiang CS, et al：Quality of life and pain in advanced stage prostate cancer：results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. J Clin Oncol 24：2828-2835, 2006

10）Eastham JA, Kelly WK, Grossfeld GD, et al：Cancer and Leukemia Group B（CALGB）90203：a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology 62（Suppl 1）：55-62, 2003

11）Bolla M, Collette L, Blank L, et al：Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer（an EORTC study）：a phase Ⅲ randomised trial. Lancet 360：103-106, 2002

12）Messing EM, Manola J, Yao J, et al：Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7：472-479, 2006

13）McLeod DG, See WA, Klimberg I, et al：The bicalutamide 150mg early prostate cancer program：findings of the North American trial at 7.7-year median followup. J Urol 176：75-80, 2006

14）Bolla M, van Poppel H, Collette L, et al：Postoperative radiotherapy after radical prostatectomy：a randomised controlled trial（EORTC trial 22911）. Lancet 366：572-578, 2005

15）D'Amico AV, Manola J, Loffredo M, et al：6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer：a randomized controlled trial. JAMA 292：821-827, 2004

16）Pilepich MV, Winter K, John MJ, et al：Phase Ⅲ radiation therapy oncology group（RTOG）trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50：1243-1252, 2001

17）Bolla M, Gonzalez D, Warde P, et al：Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337：295-300, 1997

18）Speight JL and Roach M 3rd：Radiotherapy in the management of clinically localized prostate cancer：evolving standards, consensus, controversies and new directions. J Clin Oncol 23：8176-8185, 2005

19）Chodak GW, Thisted RA, Gerber GS, et al：Results of conservative management of clinically localized prostate cancer. N Engl J Med 330：242-248, 1994

20）Miyamoto H and Messing EM：Early versus late hormonal therapy for prostate cancer. Curr Urol Rep 5：188-196, 2004

21）Partin AW and Rodriguez R：The molecular biology, endocrinology, and physiology of the prostate and seminal vesicle. In：Campbell's Urology. 8th edition. edited by Walsh P, et al, Saunders, Philadelphia, vol 2, chapt 37, pp1237-1296, 2002

22）Labrie F, Belanger A, Dupont A, et al：Science behind total androgen blockade：from gene to combination therapy. Clin Invest Med 16：475-492, 1993

23）Nishiyama T, Hashimoto Y and Takahashi K：The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin Cancer Res 10：7121-7126, 2004

24）Labrie F, Dupont A, Belanger A, et al：New hormonal therapy in prostatic carcinoma：combined treatment with an LHRH agonist and an antiandrogen. Clin Invest Med 5：267-275, 1982

25）Crawford ED, Eisenberger MA, McLeod DG, et al：A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321：419-424, 1989

26）Eisenberger MA, Blumenstein BA, Crawford ED, et al：Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 339：1036-1042, 1998

27）Prostate Cancer Trialists' Collaborative Group：Maximum androgen blockade in advanced prostate cancer：an overview of the randomised trials. Lancet 355：1491-1498, 2000

28）Brucho vs ky N, Rennie PS, Coldman AJ, et al：Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 50：2275-2282, 1990

29）Bhandari MS, Crook J and Hussain M：Should intermittent androgen deprivation be used in routine clinical practice? J Clin Oncol 23：8212-8218, 2005

30）Saad F, Gleason DM, Murray R, et al：A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94：1458-1468, 2002

31）Saad F, McKiernan J and Eastham J：Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis. Urol Oncol 24：4-12, 2006

32）Weckermann D and Harzmann R：Hormone therapy in prostate cancer：LHRH antagonists versus LHRH analogues. Eur Urol 46：279-283, 2004

33）Doehn C, Sommerauer M and Jocham D：Drug evaluation：Degarelix-a potential new therapy for prostate cancer. Idrugs 9：565-572, 2006